A new approach to support specialist prescribing of bDMARDs
Arthritis Australia is part of an eight-member Consortium led by NPS MedicineWise, which is the successful recipient of the ‘Value in Prescribing biological disease-modifying anti-rheumatic drugs (bDMARDs)’ government grant.
The grant will fund a project to improve the use of bDMARDs to ensure the best health and economic outcomes from investment in these therapies.
NPS MedicineWise media release – bDMARDS September 2019 (002)
Discover more...
-
Building the Case for a National Arthritis & Musculoskeletal Research Mission
On March 30 we launched our new report, Evaluation of Preferred Investment Models for Arthritis and Musculoskeletal Research, making a powerful case for a dedicated...
-
Arthritis Australia appoints Chief Executive Officer
MEDIA RELEASE – FOR IMMEDIATE RELEASE3 February 2026 Arthritis Australia today announced the appointment of Louise Hardy as Chief Executive Officer, following her tenure as...
-
Landmark Research Mission gives hope to 7 million Australians living with the pain of arthritis and musculoskeletal conditions
Media Release Arthritis Australia has welcomed the Albanese Government’s announcement today of a dedicated Medical Research Future Fund (MRFF) Mission of $100 million for Arthritis...
Sign up to Arthritis Insights
Regular updates, news and research findings delivered to your inbox:
